biostudies-literatureUnknown12(2)Wang H<h4>Background</h4>Despite immune checkpoint inhibitors (ICI) being widely used to treat patients with advanced non-small cell lung cancer (NSCLC), few studies examine the role of ICI in patients with proto-oncogene B-Raf, serine/threonine kinase (<i>BRAF</i>) mutations.<h4>Methods</h4>A retrospective study was conducted for patients with <i>BRAF</i>-mutant NSCLC who received treatment at Shanghai Pulmonary Hospital between 2014 and 2022. Primary end point was progression-free survival (PFS). Secondary end point was best response (RECIST, version 1.1).<h4>Results</h4>The study involved a total of 34 patients with 54 treatments recorded. The median PFS for the whole cohort was 5.8 months and the overall objective response rate (ORR) was 24%. Patients who were treated with ICI combined with chemotherapy reported a median PFS of 12.6 months and an ORR of 44%. Those who were treated with non-ICI therapy came with a median PFS of 5.3 months and an ORR of 14%. Specifically, patients had better clinical benefits with first-line ICI-combined therapy. The PFS was 18.5 months whereas that of non-ICI group was 4.1 months. The ORR was 56% in ICI-combined group and 10% in non-ICI cohort.<h4>Conclusions</h4>The findings observed an evidential and significant susceptibility to ICIs combined therapy in patients with <i>BRAF</i>-mutant NSCLC, especially in first-line treatment.Translational lung cancer research219-229https://www.ebi.ac.uk/biostudies/studies/S-EPMC9989805biostudies-literatureEfficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring <i>BRAF</i> mutations.PMC9989805Tang ZChen PZhao CMao SWang HJiang TJia KYe LLi XCai CGuo HZhou CCheng LZhou FChen XShi JfalseEfficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring <i>BRAF</i> mutations.<h4>Background</h4>Despite immune checkpoint inhibitors (ICI) being widely used to treat patients with advanced non-small cell lung cancer (NSCLC), few studies examine the role of ICI in patients with proto-oncogene B-Raf, serine/threonine kinase (<i>BRAF</i>) mutations.<h4>Methods</h4>A retrospective study was conducted for patients with <i>BRAF</i>-mutant NSCLC who received treatment at Shanghai Pulmonary Hospital between 2014 and 2022. Primary end point was progression-free survival (PFS). Secondary end point was best response (RECIST, version 1.1).<h4>Results</h4>The study involved a total of 34 patients with 54 treatments recorded. The median PFS for the whole cohort was 5.8 months and the overall objective response rate (ORR) was 24%. Patients who were treated with ICI combined with chemotherapy reported a median PFS of 12.6 months and an ORR of 44%. Those who were treated with non-ICI therapy came with a median PFS of 5.3 months and an ORR of 14%. Specifically, patients had better clinical benefits with first-line ICI-combined therapy. The PFS was 18.5 months whereas that of non-ICI group was 4.1 months. The ORR was 56% in ICI-combined group and 10% in non-ICI cohort.<h4>Conclusions</h4>The findings observed an evidential and significant susceptibility to ICIs combined therapy in patients with <i>BRAF</i>-mutant NSCLC, especially in first-line treatment.2023-01-01T00:00:00Z2023 Feb2024-11-08T12:55:20.267Z2024-11-08T12:55:20.267ZS-EPMC99898053689592610.21037/tlcr-22-613